Fosun Pharmaceutical announced that since the Nanjing Fund has entered the withdrawal period, after negotiations between the parties, all partners, including Ningbo Fuying, the holding subsidiary of the company, agreed to reduce the amount of capital already pledged and unpaid shares of the Nanjing Fund. The total amount of capital reduction was 434 million yuan, of which the Group reduced its pledged investment by 267 million yuan. After the capital reduction is completed, the total amount of capital pledged by the Nanjing Fund will be reduced from 797 million yuan to 363 million yuan, and it is still a subsidiary within the scope of the company's consolidated statements. Since Nanjing Fuxin, the capital reduction party, is a related party of the company, this capital reduction constitutes a related transaction. It has already been reviewed and approved by the company's board of directors, and there is no need to submit it to the shareholders' meeting for approval.

Fosun Pharmaceutical announced that since the Nanjing Fund has entered the withdrawal period, after negotiations between the parties, all partners, including Ningbo Fuying, the holding subsidiary of the company, agreed to reduce the amount of capital already pledged and unpaid shares of the Nanjing Fund. The total amount of capital reduction was 434 million yuan, of which the Group reduced its pledged investment by 267 million yuan. After the capital reduction is completed, the total amount of capital pledged by the Nanjing Fund will be reduced from 797 million yuan to 363 million yuan, and it is still a subsidiary within the scope of the company's consolidated statements. Since Nanjing Fuxin, the capital reduction party, is a related party of the company, this capital reduction constitutes a related transaction. It has already been reviewed and approved by the company's board of directors, and there is no need to submit it to the shareholders' meeting for approval.